Kereos

company

About

Kereos is a biotechnology company developing molecular imaging agents and therapeutics to treat cancer and cardiovascular diseases.

  • 1 - 10

Details

Last Funding Type
Series B
Last Funding Money Raised
$19.50M
Industries
Biotechnology,Health Care,Life Science,Therapeutics
Founded date
Jan 1, 1999
Number Of Employee
1 - 10
Operating Status
Active

Kereos, Inc., a biotechnology company, develops targeted molecular imaging agents and therapeutics to detect and treat cancer and cardiovascular disease. The company offers KI-0001, a magnetic resonance imaging (MRI) agent for tumor detection that finds tumors and highlights growing regions in the tumor margin; and KI-100X, a targeted chemotherapeutics for solid tumors, which reduces angiogenesis in tumor and atherosclerosis models, as well as inhibits tumor growth. It also provides KI-0002, an MRI agent for cardiovascular disease detection via an undisclosed biomarker; KI-1004, an anti-restenotic that inhibits restenosis while preserving re-endotheliazation in angioplasty models; and KM-4419, a targeted chemotherapeutic for solid tumors that synergizes with several chemotherapeutics in blocking tumor growth and increasing survival. In addition, the company works with pharmaceutical and imaging companies for the development and commercialization of cardiovascular disease MRI agents, as well as development of molecular imaging systems. Kereos, Inc. was founded in 1999 and is based in St. Louis, Missouri.

Funding Rounds

Number of Funding Rounds
Total Funding Amount
3
$19.50M
Kereos has raised a total of $19.50M in funding over 2 rounds. Their latest funding was raised on Sep 30, 2014 from a Debt Financing round.
Announced Date Round Money Raised Number of Investors Lead Investors Post Valuation
Sep 30, 2014 Debt Financing 1 Detail
Jan 31, 2014 Debt Financing 1 Detail
Sep 20, 2005 Series B $19.50M 1 Detail

Investors

Number of Lead Investors
Number of Investors
1
Kereos is funded by 1 investors. Advantage Capital are the most recent investors.
Investor Name Lead Investor Funding Round
Advantage Capital Debt Financing